FOSFOMYCIN: A SUMMARY OF A WELL-KNOWN DRUG AND PROSPECTS FOR USE IN SURGICAL PRACTICE
DOI:
https://doi.org/10.11603/1811-2471.2022.v.i3.12949Keywords:
fosfomycin, resistant gram-negative and gram-positive bacteria, surgical infection, combination antibacterial therapyAbstract
SUMMARY. In this article, we present an overview of scientific sources on the use of fosfomycin. It is an antibacterial drug that returns to the arsenal of antibiotics for the treatment of patients with surgical infection.
The aim – The authors presented the prospects for the use of fosfomycin in modern antibiotic regimens for the treatment of patients with various forms of surgical infection.
Material and Methods. We used bibliosystematic and analytical methods of searching and analyzing scientific information obtained from scientific publications with an impact factor. We searched the databases Pubmed, medLine, ClinicalKey. The search included publications from the last 10 years.
Results. Fosfomycin was synthesized almost five decades ago. This antibiotic retains activity against many multidrug-resistant strains and pathogens with increased resistance. Fosfomycin is characterized by a minimal degree of interaction with other drugs and has a relatively favorable safety profile. Many clinical studies have proven the effectiveness of the drug in the treatment of patients with urinary tract and respiratory infections, infectious lesions of bones, joints, skin and soft tissues, neuroinfection. The researchers found that fosfomycin has significant potential for use in cardiac surgery, transplantation, prevention of surgical infection in colorectal surgery.
Conclusions. Fosfomycin has high clinical efficacy in the treatment of surgical patients with community-acquired and nosocomial infectious diseases with different localization. Fosfomycin is effective in monotherapy and in combination with other antibiotics. Data from studies on the use of fosfomycin in the literature demonstrate significant potential for the use of this drug as an adjunct in cases of infectious complications in patients in intensive care units.
References
Schaeffer, E.M. (2015). Re: Is Fosfomycin a Potential Treatment Alternative for Multidrug-Resistant Gram-Negative Prostatitis? The Journal of Urology, 194(6), 1642. DOI: 10.1016/j.juro.2015.09.010.
Bader, M.S., Loeb, M., Leto, D., & Brooks, A.A. (2020). Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgraduate Medicine, 132(3), 234-250. DOI: 10.1080/ 00325481.2019.1680052.
Falagas, M.E., Athanasaki, F., Voulgaris, G.L., Triarides, N.A., & Vardakas, K.Z. (2019). Resistance to fosfomycin: Mechanisms, Frequency and Clinical Consequences. International Journal of Antimicrobial Agents, 53(1), 22-28. DOI: 10.1016/j.ijantimicag.2018.09.013.
Castañeda-García, A., Blázquez, J., & Rodríguez-Rojas, A. (2013). Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance. Antibiotics (Basel, Switzerland), 2(2), 217-236. DOI: 10.3390/antibiotics2020217.
Falagas, M.E., Vouloumanou, E.K., Togias, A.G., Karadima, M., Kapaskelis, A.M., Rafailidis, P.I., & Athanasiou, S. (2010). Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. The Journal of Antimicrobial Chemotherapy, 65(9), 1862-1877. DOI: 10.1093/jac/dkq237.
Falagas, M.E., Vouloumanou, E.K., Samonis, G., & Vardakas, K.Z. (2016). Fosfomycin. Clinical Microbiology Reviews, 29(2), 321-347. DOI: 10.1128/CMR.00068-15.
Kisa, E., Altug, M.U., Gurbuz, O.A., & Ozdemir, H. (2017). Fosfomycin: a good alternative drug for prostate biopsy prophylaxis the results of a prospective, randomized trial with respect to risk factors. International Braz. J. Urol. : Official Journal of The Brazilian Society of Urology, 43(6), 1068-1074. DOI: 10.1590/S1677-5538.IBJU. 2016.0619.
Sardar, A., Basireddy, S.R., Navaz, A., Singh, M., & Kabra, V. (2017). Comparative Evaluation of Fosfomycin Activity with other Antimicrobial Agents against E.coli Isolates from Urinary Tract Infections. Journal of Clinical and Diagnostic Research : JCDR, 11(2), DC26-DC29. DOI: 10.7860/JCDR/2017/23644.9440.
Sastry, S., & Doi, Y. (2016). Fosfomycin: Resurgence of an old companion. Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy, 22(5), 273-280. DOI: 10.1016/j.jiac.2016.01.010.
Karaiskos, I., Lagou, S., Pontikis, K., Rapti, V., & Poulakou, G. (2019). The "Old" and the "New" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. Frontiers in Public Health, 7, 151. DOI: 10.3389/fpubh.2019.00151.
Golan, Y. (2015). Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options. BMC Infectious Diseases, 15, 313. DOI: 10.1186/s12879-015-1054-1.
Iarikov, D., Wassel, R., Farley, J., & Nambiar, S. (2015). Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database. Infectious Diseases and Therapy, 4(4), 433-458. DOI: 10.1007/s40121-015-0092-8.
Wang, M., Li, Y., Zheng, L., & Guan, W. (2018). Zhonghua wei chang wai ke za zhi. Chinese Journal of Gastrointestinal Surgery, 21(12), 1387-1390.
Salmanov, А.G., & Usenko, А.Y. (2018). Аntibiotic resistance of nosocomial strains of Staphylococcus aureus in surgical stationaries of Ukraine: results of multicenter investigation (2015 – 2016 yrs). Klinicheskaia Khirurgiia – Clinical Surgery, 85(5), 5-9. DOI: 10.26779/2522-1396. 2018.05.05.
Lazoryshynetz, V.V., Spysarenko, S.P., Krykunov, A.A., & Malysheva, T.A. (2017). Antiobiotic resistance in the current realities of cardiac surgery. Ukrainian Journal of Cardiovascular Surgery, 1(27), 110-114. Retrieved from http://cvs.org.ua/index.php/ujcvs/article/view/189.
Dietl, B., Martínez, L.M., Calbo, E., & Garau, J. (2020). Update on the role of ceftazidime-avibactam in the management of carbapenemase-producing Enterobacterales. Future Microbiology, 15, 473-484. DOI: 10.2217/fmb-2020-0012.
Gupta, K., Hooton, T.M., Naber, K.G., Wullt, B., Colgan, R., Miller, L.G., Moran, G.J., … & Soper, D.E., Infectious Diseases Society of America, & European Society for Microbiology and Infectious Diseases (2011). International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 52(5), e103-e120. DOI: 10.1093/cid/ciq257.
Grabein, B., Graninger, W., Rodríguez Baño, J., Dinh, A., & Liesenfeld, D.B. (2017). Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. Clinical Microbiology and Infection : The Official Publication of The European Society of Clinical Microbiology and Infectious Diseases, 23(6), 363-372. DOI: 10.1016/j.cmi.2016.12.005.
Dyachenko, V., Mariushchenko, A., Chygyrynska, N., & Kutsay, N. (2020). The study of antimicrobial activity of combinations of fosfomycin with cefepime and fosfomycin with tienam in respect polyantibiotic-resistant strains of Enterobacteria. Annals of Mechnikov’s Institute, (2), 40-42. Retrieved from http://journals.uran.ua/ami/article/view/191023.
Tikhilov, R., Bozhkova, S., Denisov, A., Labutin, D., Shubnyakov, I., Razorenov, V., Artyukh, V., & Klitsenko, O. (2016). Risk factors and a prognostic model of hip periprosthetic infection recurrence after surgical treatment using articulating and non-articulating spacers. International Orthopaedics, 40(7), 1381-1387. DOI: 10.1007/s00264-015-3072-4.
Costelloe, C., Metcalfe, C., Lovering, A., Mant, D., & Hay, A.D. (2010). Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ (Clinical research ed.), 340, c2096. DOI: 10.1136/bmj.c2096.
Kolasiński, W. (2018). Surgical site infections - review of current knowledge, methods of prevention. Polski Przeglad Chirurgiczny, 91(4), 41-47. DOI: 10.5604/01.3001. 0012.7253.
Fodor, A., Abate, B.A., Deák, P., Fodor, L., Gyenge, E., Klein, M.G., Koncz, Z., Muvevi, J., Ötvös, L., Székely, G., Vozik, D., & Makrai, L. (2020). Multidrug Resistance (MDR) and Collateral Sensitivity in Bacteria, with Special Attention to Genetic and Evolutionary Aspects and to the Perspectives of Antimicrobial Peptides-A Review. Pathogens (Basel, Switzerland), 9(7), 522. DOI: 10.3390/pathogens9070522.
Grabein, B., Graninger, W., Rodríguez Baño, J., Dinh, A., & Liesenfeld, D.B. (2017). Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. Clinical Microbiology and Infection : The Official Publication of The European Society of Clinical Microbiology and Infectious Diseases, 23(6), 363-372. DOI: 10.1016/j.cmi.2016.12.005.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Achievements of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
